Cargando…
Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
BACKGROUND: The ongoing coronavirus disease (COVID-19) pandemic has major impacts on health systems, the economy and society. Assessing infection attack rates in the population is critical for estimating disease severity and herd immunity which is needed to calibrate public health interventions. We...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Centre for Disease Prevention and Control (ECDC)
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189648/ https://www.ncbi.nlm.nih.gov/pubmed/32347204 http://dx.doi.org/10.2807/1560-7917.ES.2020.25.16.2000421 |
_version_ | 1783527541003255808 |
---|---|
author | Perera, Ranawaka APM Mok, Chris KP Tsang, Owen TY Lv, Huibin Ko, Ronald LW Wu, Nicholas C Yuan, Meng Leung, Wai Shing Chan, Jacky MC Chik, Thomas SH Choi, Chris YC Leung, Kathy Chan, Kin Ho Chan, Karl CK Li, Ka-Chi Wu, Joseph T Wilson, Ian A Monto, Arnold S Poon, Leo LM Peiris, Malik |
author_facet | Perera, Ranawaka APM Mok, Chris KP Tsang, Owen TY Lv, Huibin Ko, Ronald LW Wu, Nicholas C Yuan, Meng Leung, Wai Shing Chan, Jacky MC Chik, Thomas SH Choi, Chris YC Leung, Kathy Chan, Kin Ho Chan, Karl CK Li, Ka-Chi Wu, Joseph T Wilson, Ian A Monto, Arnold S Poon, Leo LM Peiris, Malik |
author_sort | Perera, Ranawaka APM |
collection | PubMed |
description | BACKGROUND: The ongoing coronavirus disease (COVID-19) pandemic has major impacts on health systems, the economy and society. Assessing infection attack rates in the population is critical for estimating disease severity and herd immunity which is needed to calibrate public health interventions. We have previously shown that it is possible to achieve this in real time to impact public health decision making. AIM: Our objective was to develop and evaluate serological assays applicable in large-scale sero-epidemiological studies. METHODS: We developed an ELISA to detect IgG and IgM antibodies to the receptor-binding domain (RBD) of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated its sensitivity and specificity in combination with confirmatory microneutralisation (MN) and 90% plaque reduction neutralisation tests (PRNT(90)) in 51 sera from 24 patients with virologically confirmed COVID-19 and in age-stratified sera from 200 healthy controls. RESULTS: IgG and IgM RBD ELISA, MN and PRNT(90) were reliably positive after 29 days from illness onset with no detectable cross-reactivity in age-stratified controls. We found that PRNT(90) tests were more sensitive in detecting antibody than MN tests carried out with the conventional 100 tissue culture infectious dose challenge. Heparinised plasma appeared to reduce the infectivity of the virus challenge dose and may confound interpretation of neutralisation test. CONCLUSION: Using IgG ELISA based on the RBD of the spike protein to screen sera for SARS-CoV-2 antibody, followed by confirmation using PRNT(90), is a valid approach for large-scale sero-epidemiology studies. |
format | Online Article Text |
id | pubmed-7189648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | European Centre for Disease Prevention and Control (ECDC) |
record_format | MEDLINE/PubMed |
spelling | pubmed-71896482020-04-30 Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 Perera, Ranawaka APM Mok, Chris KP Tsang, Owen TY Lv, Huibin Ko, Ronald LW Wu, Nicholas C Yuan, Meng Leung, Wai Shing Chan, Jacky MC Chik, Thomas SH Choi, Chris YC Leung, Kathy Chan, Kin Ho Chan, Karl CK Li, Ka-Chi Wu, Joseph T Wilson, Ian A Monto, Arnold S Poon, Leo LM Peiris, Malik Euro Surveill Research BACKGROUND: The ongoing coronavirus disease (COVID-19) pandemic has major impacts on health systems, the economy and society. Assessing infection attack rates in the population is critical for estimating disease severity and herd immunity which is needed to calibrate public health interventions. We have previously shown that it is possible to achieve this in real time to impact public health decision making. AIM: Our objective was to develop and evaluate serological assays applicable in large-scale sero-epidemiological studies. METHODS: We developed an ELISA to detect IgG and IgM antibodies to the receptor-binding domain (RBD) of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated its sensitivity and specificity in combination with confirmatory microneutralisation (MN) and 90% plaque reduction neutralisation tests (PRNT(90)) in 51 sera from 24 patients with virologically confirmed COVID-19 and in age-stratified sera from 200 healthy controls. RESULTS: IgG and IgM RBD ELISA, MN and PRNT(90) were reliably positive after 29 days from illness onset with no detectable cross-reactivity in age-stratified controls. We found that PRNT(90) tests were more sensitive in detecting antibody than MN tests carried out with the conventional 100 tissue culture infectious dose challenge. Heparinised plasma appeared to reduce the infectivity of the virus challenge dose and may confound interpretation of neutralisation test. CONCLUSION: Using IgG ELISA based on the RBD of the spike protein to screen sera for SARS-CoV-2 antibody, followed by confirmation using PRNT(90), is a valid approach for large-scale sero-epidemiology studies. European Centre for Disease Prevention and Control (ECDC) 2020-04-23 /pmc/articles/PMC7189648/ /pubmed/32347204 http://dx.doi.org/10.2807/1560-7917.ES.2020.25.16.2000421 Text en This article is copyright of the authors or their affiliated institutions, 2020. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made. |
spellingShingle | Research Perera, Ranawaka APM Mok, Chris KP Tsang, Owen TY Lv, Huibin Ko, Ronald LW Wu, Nicholas C Yuan, Meng Leung, Wai Shing Chan, Jacky MC Chik, Thomas SH Choi, Chris YC Leung, Kathy Chan, Kin Ho Chan, Karl CK Li, Ka-Chi Wu, Joseph T Wilson, Ian A Monto, Arnold S Poon, Leo LM Peiris, Malik Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 |
title | Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 |
title_full | Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 |
title_fullStr | Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 |
title_full_unstemmed | Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 |
title_short | Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 |
title_sort | serological assays for severe acute respiratory syndrome coronavirus 2 (sars-cov-2), march 2020 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189648/ https://www.ncbi.nlm.nih.gov/pubmed/32347204 http://dx.doi.org/10.2807/1560-7917.ES.2020.25.16.2000421 |
work_keys_str_mv | AT pereraranawakaapm serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT mokchriskp serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT tsangowenty serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT lvhuibin serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT koronaldlw serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT wunicholasc serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT yuanmeng serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT leungwaishing serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT chanjackymc serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT chikthomassh serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT choichrisyc serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT leungkathy serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT chankinho serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT chankarlck serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT likachi serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT wujosepht serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT wilsoniana serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT montoarnolds serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT poonleolm serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 AT peirismalik serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020 |